跳轉至內容
Merck
全部照片(1)

文件

ALP60

Sigma-Aldrich

Apolipoprotein C-III, human

同義詞:

ApoCIII

登入查看組織和合約定價


About This Item

分類程式碼代碼:
12352202
eCl@ss:
32160405
NACRES:
NA.41

生物源

human

品質等級

100
300

化驗

>95% (SDS-PAGE)

形狀

liquid

製造商/商標名

Chemicon®

NCBI登錄號

UniProt登錄號

一般說明

Apolipoprotein C-III (APOC3) is a multifaceted protein, localized on circulating triglyceride-rich lipoproteins (TRLs), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very-low-density lipoprotein (VLDL). The APOC3 gene is mapped to the human chromosome 11q23.3. It is mainly expressed in hepatocytes and to a lesser extent in enterocytes.
Product Source: Human plasma tested negative for HBsAg and HIV-I, HIV-II, HBc and Hepatitis C antibodies. All blood products should be treated as potentially infectious.

應用

Apolipoprotein C-III (APOC3), human has been used to determine its effect reconstituted high-density lipoprotein (rHDL) containing apoA-I. It has also been used to test the effects of the exogenous exchangeable apolipoproteins on low-density lipoprotein (LDL) binding to heparin.

生化/生理作用

Apolipoprotein C-III (APOC3) is involved in triglyceride metabolism and atherosclerotic lesion formation. It also regulates pathological processes involved in atherosclerosis. APOC3 stimulates hypertriglyceridemia (HTG) through various mechanisms. It functions as a lipoprotein lipase (LPL) inhibitor and also interrupts the clearance of triglyceride-rich lipoproteins (TRLs)-remnants. Mutations in the gene lead to lower plasma glycerides and lower cardiovascular disease risk.
The physiological role of Apo CIII is unknown. It is suggested that Apo CIII may inhibit the activation of lipoprotein lipase by Apo CII.

外觀

Liquid in 10 mM NH4HCO3, pH 7.4.

儲存和穩定性

Maintain at -20ºC or below in undiluted aliquots for up to 12 months. Avoid repeated freeze/thaw cycles. All blood products should be treated as potentially infectious.

法律資訊

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

免責聲明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

儲存類別代碼

12 - Non Combustible Liquids

水污染物質分類(WGK)

nwg

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Jan Borén et al.
Frontiers in endocrinology, 11, 474-474 (2020-08-28)
Cardiovascular disease (CVD) is the leading cause of death globally. It is well-established based on evidence accrued during the last three decades that high plasma concentrations of cholesterol-rich atherogenic lipoproteins are causatively linked to CVD, and that lowering these reduces
Rayabarapu Pranavchand et al.
Lipids in health and disease, 16(1), 116-116 (2017-06-15)
Given the characteristic atherogenic dyslipidemia of south Indian population and crucial role of APOA1, APOC3, APOA4 and APOA5 genes clustered in 11q23.3 chromosomal region in regulating lipoprotein metabolism and cholesterol homeostasis, a large number of recently identified variants are to
Kyung-Hyun Cho
Molecules and cells, 27(3), 291-297 (2009-03-28)
Apolipoprotein (apo) C-III is a marker protein of triacylglycerol (TG)-rich lipoproteins and high-density lipoproteins (HDL), and has been proposed as a risk factor of coronary heart disease. To compare the physiologic role of reconstituted HDL (rHDL) with or without apoC-III
Alison B Kohan
Current opinion in endocrinology, diabetes, and obesity, 22(2), 119-125 (2015-02-19)
The purpose of this article is to summarize the recent epidemiological, basic science, and pharmaceutical research linking apolipoprotein C-III (apoC-III) with the development and treatment of cardiovascular disease (CVD). ApoC-III is an important emerging target linking hypertriglyceridemia with CVD. ApoC-III
Jihoe Kim et al.
BMB reports, 43(8), 535-540 (2010-08-28)
Patients with hemorrhagic fever with renal syndrome (HFRS) often exhibit altered serum lipid and lipoprotein profile during the oliguric phase of the disease. Serum lipid and lipoprotein profiles were assessed during the oliguric and recovery phases in six male patients

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務